Breast MRI May Be Safely Omitted From Diagnostic Workup in Certain Patients With Early-stage, HR-negative Breast Cancer
Preoperative MRI had no impact on five-year recurrence rates SAN ANTONIO – Patients with stage 1 or 2, hormone...
Search/Filter
Loading...
Sentinel Lymph Node Biopsy May Be Safely Omitted in Some Patients With Early-stage Breast Cancer
Omission of sentinel lymph node biopsy did not change five-year recurrence rates SAN ANTONIO – Skipping sentinel lymph node...
A Multimodal AI Model May Improve Recurrence Risk Stratification in Early Breast Cancer
New model provided better prognostic information for recurrence in HR-positive, HER2-negative breast cancer than the Oncotype DX 21-gene recurrence...
Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers
SAN ANTONIO – Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they...
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial
Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to...
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial
SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant...
Elironrasib May Overcome Resistance to Prior KRAS G12C Inhibition in Non-small Cell Lung Cancer
The small molecule KRAS inhibitor elironrasib targets the active GTP-bound form of KRAS G12C and led to encouraging responses...
New Targeted Therapy Shows Promise for Patients With Advanced Bladder Cancer
BOSTON – FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs...
Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct Cancer
BOSTON – Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led...
Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer
Patients with brain metastasis experienced responses in the phase I clinical trial BOSTON – Zocilurtatug pelitecan (zoci), also known as ZL-1310, an...